Country: Israel
Language: English
Source: Ministry of Health
LORCASERIN HYDROCHLORIDE HEMIHYDRATE
ABIC MARKETING LTD, ISRAEL
A08AA11
FILM COATED TABLETS
LORCASERIN HYDROCHLORIDE HEMIHYDRATE 10.4 MG
PER OS
Required
EISAI CO. LTD, JAPAN
LORCASERIN
Belviq is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:• 30 kg/m2 or greater (obese), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)
2017-02-15
Prescriber Brochure This Prescriber Brochure format and content has been checked and approved by the Ministry of Health in March 2017 BELVIQ 10 MG TABLETS PRESCRIBER GUIDE _THIS DOCUMENT DOES NOT INCLUDE COMPLETE DATA FOR THE PRESCRIBER. FOR COMPLETE DATA PLEASE _ _REFER TO THE PHYSICIAN'S PRESCRIBING INFORMATION._ Belviq is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese), or 27 kg/m 2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes) BELVIQ SHOULD ONLY BE GIVEN FOR PERIODS UP TO TWO YEARS. Belviq Prescriber Guide contains important information concerning the safe and appropriate use of Belviq. For any further information please refer to Belviq Physician's Prescribing Information. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form http://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.gov.il Or to Teva by e-mail Safety Israel LSO_IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDERS_ VALVULAR HEART DISEASE Regurgitant cardiac valvular disease, primarily affecting the mitral and/or aortic valves, has been reported in patients who took serotonergic drugs with 5-HT 2B receptor agonist activity. In clinical trials of 1-year duration, 2.4% of patients receiving BELVIQ and 2.0% of patients receiving placebo developed echocardiographic criteria for valvular regurgitation at one year (mild or greater aortic regurgitation and/or moderate or greater mitral regurgitation): none of these patients was symptomatic. The etiology of the regurgitant valvular disease is thought to be activation of 5-HT 2B receptors on cardiac interstitial cells and at therapeutic concentrations, BELVIQ is selective for 5-HT 2C receptors as compared to 5 Read the complete document
BELVIQ Tablets 19.2.2017, ME ."רשואו קדבנ ונכותו תואירבה דרשמ י"ע עבקנ הז ןולע טמרופ" ראוני רשואמ ןולע 2017 “This leaflet format has been determined by the Ministry of Health and the content thereof has been checked and approved.” Date of approval: January 2017 BELVIQ _ _ (lorcaserin hydrochloride) 10 mg _ _ film-coated tablets _ _ 1 INDICATIONS AND USAGE BELVIQ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese), or 27 kg/m 2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes) [ _see Dosage and Administration (2)_ ] Limitations of Use: Belviq should only be given for periods up to two years. The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations have not been established The effect of BELVIQ on cardiovascular morbidity and mortality has not been established 2 DOSAGE AND ADMINISTRATION The recommended dose of BELVIQ is 10 mg administered orally twice daily. Do not exceed recommended dose [ _see Warnings and Precautions (5.4)_ ]. BELVIQ can be taken with or without food. Response to therapy should be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, discontinue BELVIQ, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment [ _see Clinical Studies (14)_ ]. BMI is calculated by dividing weight (in kg) by height (in meters) squared. PRESCRIBER GUIDE This product is marketed with prescriber guide providing important safety information. Please ensure you are familiar with this material as it contains important safety information. BELVIQ Tablets 19.2.2017, ME A BMI chart Read the complete document